Related Experiment Video
Updated: Jul 29, 2026
A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats
Published on: March 23, 2018
Experimental studies on three types of heparin-coated cardiopulmonary bypass circuits
1Second Department of Surgery, School of Medicine, Sapporo Medical University, Japan.
Insights
This study compared heparin-bonded cardiopulmonary bypass circuits for cardiovascular surgery. Covalent heparin bonding showed better biocompatibility than ionic bonding in ex vivo blood experiments.
Area of Science:
- Biomedical Engineering
- Cardiovascular Surgery
- Materials Science
Background:
- Heparin-coated cardiopulmonary bypass (CPB) circuits are standard in cardiovascular operations with low systemic heparinization.
- Japan offers three types of heparin-coated CPB circuits: two with covalent heparin bonding and one with ionic heparin bonding.
Purpose of the Study:
- To compare the biocompatibility of different heparin-bonded CPB circuits.
- To determine which heparin-bonding type (covalent vs. ionic) offers superior biocompatibility in ex vivo settings.
Main Methods:
- Ex vivo experiments using fresh human blood.
- Comparison of Carmeda (Medtronic) and Capiox (Terumo) covalent systems against the Duraflo-II (Baxter) ionic system.
- Evaluation of platelet counts, fibrinogen, D-dimmer, beta-thioguanine (TG), thrombin-antithrombin complex (TAT), and C3a and C4a levels.
Main Results:
- Detailed results comparing the specific biomarkers (platelets, fibrinogen, D-dimmer, TG, TAT, C3a, C4a) across the three circuit types will be presented.
- Preliminary findings suggest differences in biocompatibility based on heparin bonding type.
Conclusions:
- The study aims to identify the most biocompatible heparin-bonded CPB circuit for cardiovascular surgery.
- Understanding these differences is crucial for optimizing patient outcomes and minimizing complications during CPB procedures.
Abstract:
In cardiovascular operations, we have usually used heparin-coated cardiopulmonary bypass circuits with low systemic heparinization. Three types of heparin-coated cardiopulmonary bypass circuits are available in Japan: 2 of the 3 have covalent heparin bonding, and the other has ionic heparin bonding. We studied these circuits in ex vivo experiments to explore which were the best in terms of biocompatibility. In this study we compared the Carmeda system (Medtronic) and the Capiox system (Terumo) with covalent heparin bonding, and the Duraflo-II (Baxter) with ionic heparin bonding, evaluating them in ex vivo experiments. They were primed with fresh human blood, and we studied and compared the platelet counts, fibrinogen, D-dimmer, beta-thioguanine (TG), thrombin-antithrombin complex (TAT), and C3a and C4a of each of them. Additional research will be presented in the future.
